Magnetic resonance guided focused high frequency ultrasound ablation for focal therapy in prostate cancer - phase 1 trial.
Sangeet GhaiNathan PerlisUri LindnerEugen HlasnyMasoom A HaiderAntonio FinelliAlexandre R ZlottaGirish S KulkarniTheodorus H van der KwastStuart A McCluskeyWalter KucharczykJohn TrachtenbergPublished in: European radiology (2018)
• Focal therapy selectively ablates locally confined, clinically significant index lesion with a margin while sparing rest of gland and adjacent vital structures. • Magnetic resonance-guided focused high frequency ultrasound surgery (MRgFUS) combines MRI with HIFU. • MRgFUS provides ability to monitor treatments in real time and allows a targeted approach for focal ablation. • MRgFUS is a feasible, safe method of noninvasively ablating low-intermediate risk PCa. • MRgFUS provides acceptable oncologic outcomes at 6 months.
Keyphrases
- high frequency
- magnetic resonance
- transcranial magnetic stimulation
- prostate cancer
- magnetic resonance imaging
- contrast enhanced
- radical prostatectomy
- minimally invasive
- high resolution
- coronary artery bypass
- radiofrequency ablation
- ultrasound guided
- drug delivery
- stem cells
- metabolic syndrome
- type diabetes
- computed tomography
- diffusion weighted imaging
- rectal cancer
- atrial fibrillation
- cancer therapy
- catheter ablation
- insulin resistance
- acute coronary syndrome
- mesenchymal stem cells
- glycemic control